Novartis withdraws EU applications to increase Exelon and Prometax indications
This article was originally published in Scrip
Executive Summary
Novartis Europharm has told the European Medicines Agency (EMA) that it wishes to withdraw its applications to extend the therapeutic indications for the medicines Exelon (rivastigmine) and Prometax (rivastigmine). The company has told the agency that it will not be able to provide the additional data needed to support expansion of the indications within the timeframe allowed in the European Union's centralised procedure. .